San Francisco startup Framework Therapeutics is also focusing on an oral, once-day by day GLP-1 drug termed GSBR-1290—the drug surpassed Wall Road’s expectations in June any time a mid-phase analyze confirmed average weight loss of around 6% and it programs to start out An additional